Inactivated vaccines, also known as killed vaccines, are a type of vaccine that utilizes viruses or bacteria that have been neutralized or killed to stimulate an immune response without causing disease. These vaccines are produced by rendering the infectious agent nonfunctional through chemical or physical methods. The inactivated agents in the vaccine cannot replicate or cause infection, making them safe for use, particularly in individuals with weakened immune systems. Inactivated vaccines typically require booster doses to maintain immunity over time. Common examples of inactivated vaccines include the polio vaccine, hepatitis A vaccine, and the whole-cell pertussis component in some versions of the DTP (diphtheria, tetanus, and pertussis) vaccine. Influenza vaccines, both injectable and some nasal spray formulations, also utilize inactivated viruses. While inactivated vaccines provide effective protection, they may require adjuvants or additional components to enhance the immune response. Their safety profile and ability to be used in various populations contribute to their widespread use in vaccination programs globally, preventing a range of infectious diseases.
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan